The Merck BACE 1 study is a Phase II study testing the safety, tolerability, and cognitive effects of the Merck BACE inhibitor drug.

Individuals 55-85 years of age with a diagnosis of mild to moderate Alzheimer’s disease may be eligible. The study includes one baseline visit, 10 in-clinic visits, and 7 phone calls.

Download a one-page overview of the study including contact information